Subscribe To

Price Alert Latest News Economic Calendar News

SHIEF / Shield Therapeutics completes the formalities on US$10mln loan

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it had completed the formalities related to a US$10mln provided by shareholder AOP Health International Management. AOP in turn has exercised its option to convert a portion of that debt into equity giving it just under 41.2mln shares. Read More

Demo Live Account See Partner Details

Content Topics

Shield

Therapeutics

Completes

Formalities

Us

10mln

Loan

Us 10mln

Stock

SHIEF

Posted: Aug 1 2022, 03:23

Author Name: Proactive Investors

SHIEF News

By Proactive Investors
October 12, 2023

Shield Therapeutics launches executive search process as CFO steps down

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that chief financial officer Hans-Peter Rudolf is stepping down from his position to purs

By Proactive Investors
October 3, 2023

Shield Therapeutics: A case of cautious optimism amid revised guidance

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which has developed a best-in-class anaemia treatment, has been going through the growing pains assoc

By Proactive Investors
September 28, 2023

Shield Therapeutics raises funds to accelerate commercial opportunity for Accrufer iron deficiency treatment in US market

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is raising up to $27.5 million of new funds to support its development of Accrufer, its iron deficiency

By Proactive Investors
July 23, 2023

Small-cap Movers: GSTechnologies takes Canada plunge, Shield Therapeutics leads in life sciences

There is life in the cryptocurrency sector yet, so it may seem. At least for GSTechnologies Ltd (LSE:GST), the London-listed financial technology smal

By Proactive Investors
July 20, 2023

Shield Therapeutics reports 173% Accrufer prescription growth

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its Accrufer iron deficiency treatment saw 173% growth in prescriptions in the second quarter, or

By Proactive Investors
April 27, 2023

Shield Therapeutics ready to go full throttle in the US

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it is ‘very' optimistic about the future as it gears up for a full US commercial push of its lea

By Proactive Investors
April 5, 2023

Shield Therapeutics appoints chief commercial officer as group readies for US sales offensive

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the developer of a breakthrough oral drug for iron deficiency, has announced the appointment of indu

By Proactive Investors
February 9, 2023

Shield Therapeutics shares jump 13%; broker sets punchy price target

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) saw its shares jump 13% following an encouraging trading update. The company's main product, Accrufer,

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.